SAB Biotherapeutics News and Activities

SAB Biotherapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

SAB Biotherapeutics is a company listed under the stock ticker SABS (US).

Acquisition, funding and merger involving SAB Biotherapeutics.

• SAB Biotherapeutics has just announced a $175 Million fundraising (posted on July 22 2025).

View the org chart displaying its 28 main executives

Most searched biographies at SAB Biotherapeutics

• Samuel Reich, Executive Chairman of the Board and Chief Executive ...
• Jay Skyler, Director
• Katie Ellias, Director

Popular executive movements at SAB Biotherapeutics

• David Zaccardelli has joined the company as Chairman of the Board  (posted on January 9 2026).
• Rita Jain has joined the company as Independent Director  (posted on January 9 2026).

Create your alert
to follow the executive moves at SAB Biotherapeutics.

SAB Biotherapeutics has 2,429 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Tempus has announced the acquisition of Personalis  (posted on July 20 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (posted on July 17 2026).
• GSK has acquired Nuvalent (posted on July 17 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by SAB Biotherapeutics

• Presentations | SAB Biotherapeutics
• Events | SAB Biotherapeutics
• News Releases | SAB Biotherapeutics
• Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics - SAb Biotherapeutics

Social media about SAB Biotherapeutics

• SAB Biotherapeutics on Wikipedia, Google News & Yahoo Finance
• SAB Biotherapeutics on LinkedIn, X (Twitter) & YouTube